Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.42 |
| ▸ | DHODH | Q02127 | 1/20 | 0.36 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 7/20 | 0.33 |
| ▸ | GRM2 | Q14416 | 3/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | OPRL1 | P41146 | 4/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20833797 | 0.92 | NR1H4 (0.40) | NR1H4DHODHMAPK14GRM2SLC6A2 | |
| SCHEMBL17839932 | 0.91 | NR1H4 (0.41) | NR1H4MAPK14GRM2 | |
| SCHEMBL30807043 | 0.89 | NR1H4 (0.41) | NR1H4DHODHHDAC9MAPK14HTR1A | |
| SCHEMBL20833740 | 0.89 | NR1H4 (0.43) | NR1H4DHODHHDAC9MAPK14HTR1A | |
| SCHEMBL20833879 | 0.89 | NR1H4 (0.41) | NR1H4DHODHHDAC9MAPK14HTR1A | |
| SCHEMBL30807047 | 0.85 | NR1H4 (0.36) | NR1H4DHODHGRM2OPRL1 | |
| SCHEMBL20833799 | 0.85 | NR1H4 (0.36) | NR1H4DHODHGRM2OPRL1 | |
| SCHEMBL19689540 | 0.80 | NR1H4 (0.46) | NR1H4MAPK14OPRL1 | |
| SCHEMBL20833733 | 0.79 | NR1H4 (0.40) | NR1H4MAPK14GRM2 | |
| SCHEMBL1097296 | 0.79 | NR1H4 (0.40) | NR1H4DHODHMAPK14GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111655680-B | Hormone receptor modulators for the treatment of metabolic mutations and fibrotic conditions and disorders | 阿德利克斯股份有限公司 | 2024-03-05 | — | — | CN | disclosed |
| US-11753410-B2 | Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorders | ARDELYX, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753410-B2 | Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorders | ARDELYX, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753410-B2 | Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorders | ARDELYX, INC. (US) | 2023-09-12 | — | — | US | disclosed |
| EP-3681881-B1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC MUTAGENIC AND FIBROTIC CONDITIONS AND DISORDERS | ARDELYX INC (US) | 2022-11-02 | — | — | EP | disclosed |
| US-20210380585-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC MUTAGENIC AND FIBROTIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2021-12-09 | — | — | US | disclosed |
| WO-2019055808-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC MUTAGENIC AND FIBROTIC CONDITIONS AND DISORDERS | ARDELYX, INC. (US) | 2019-03-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210380585-A1 | HORMONE RECEPTOR MODULATORS FOR TREATING METABOLIC MUTAGENIC AND FIBROTIC CONDITIONS AND DISORDERS | NR1H4, FXR1, FXR2 | NR1H4 1/4885DHODH 4137/4885HDAC9 2194/4885 |
| US-11753410-B2 | Hormone receptor modulators for treating metabolic mutagenic and fibrotic conditions and disorders | NR1H4, FXR1, FXR2 | NR1H4 1/4885DHODH 4137/4885HDAC9 2194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.